BELLUS Health Inc. (BLU): Price and Financial Metrics


BELLUS Health Inc. (BLU): $8.28

0.65 (+8.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLU to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BLU POWR Grades


  • Sentiment is the dimension where BLU ranks best; there it ranks ahead of 62.94% of US stocks.
  • BLU's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • BLU ranks lowest in Momentum; there it ranks in the 12th percentile.

BLU Stock Summary

  • BELLUS Health Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.79% of US listed stocks.
  • For BLU, its debt to operating expenses ratio is greater than that reported by merely 5.91% of US equities we're observing.
  • With a price/sales ratio of 40,978.19, BELLUS Health Inc has a higher such ratio than 99.98% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BELLUS Health Inc are FSR, URG, CALT, MRSN, and EQS.
  • Visit BLU's SEC page to see the company's official filings. To visit the company's web site, go to www.bellushealth.com.

BLU Price Target

For more insight on analysts targets of BLU, see our BLU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.20 Average Broker Recommendation 1.43 (Moderate Buy)

BLU Stock Price Chart Interactive Chart >

Price chart for BLU

BLU Price/Volume Stats

Current price $8.28 52-week high $9.84
Prev. close $7.63 52-week low $2.60
Day low $7.57 Volume 780,000
Day high $8.43 Avg. volume 941,982
50-day MA $7.78 Dividend yield N/A
200-day MA $6.51 Market Cap 883.87M

BELLUS Health Inc. (BLU) Company Bio


BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.


BLU Latest News Stream


Event/Time News Detail
Loading, please wait...

BLU Latest Social Stream


Loading social stream, please wait...

View Full BLU Social Stream

Latest BLU News From Around the Web

Below are the latest news stories about BELLUS Health Inc that investors may wish to consider to help them evaluate BLU as an investment opportunity.

LifeSci Capital Keeps Their Buy Rating on BELLUS Health (BLU)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on January 24 and set a price target of $17.00. The company's shares closed last Wednesday at $5.90. According to TipRanks.com, Slutsky is ranked 0 out of 5 stars with an average return of -4.8% and a 34.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $16.33 average price target, representing a 169.5% upside. In a report issued on January 25, H.C.

Howard Kim on TipRanks | January 27, 2022

BELLUS Shares Have More Room to Run, Says Analyst

The week started in the best possible way for BELLUS Health (BLU) stock. While the main indexes bled in Monday’s session, BLU shares took the up escalator, surging by 48% following the announcement of positive clinical trial results. The company is testing lead candidate BLU-5937 as a potential therapy for refractory chronic cough (RCC). Topline results from the Phase 2b SOOTHE study of the P2X3 inhibitor showed the drug made a statistically meaningful difference; after 28 days of treatment there was a significant improvement to RCC patients' daily cough frequency, with a placebo-adjusted cough reduction of 34.4% in the 50mg cohort and a 34.2% drop in the 200mg group.

Marty Shtrubel on TipRanks | December 14, 2021

BELLUS Health (BLU) Receives a Buy from LifeSci Capital

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $18.00. The company's shares closed last Monday at $8.30. According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 6.1% and a 38.6% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. Currently, the analyst consensus on BELLUS Health is a Strong Buy with an average price target of $16.00, implying a 92.8% upside from current levels.

Christine Brown on TipRanks | December 14, 2021

BELLUS Health (BLU) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BELLUS Health (BLU – Research Report) today and set a price target of $14.00. The company's shares closed last Monday at $8.63. According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.7% and a 40.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Deciphera Pharmaceuticals, and Global Blood Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $15.75 average price target, implying a 99.1% upside from current levels.

Catie Powers on TipRanks | December 13, 2021

ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today

Arena Pharmaceuticals (ARNA) stock is flying higher on Monday thanks to a huge $6.7 billion acquisition deal with Pfizer (PFE).

William White on InvestorPlace | December 13, 2021

Read More 'BLU' Stories Here

BLU Price Returns

1-mo 3.24%
3-mo 28.77%
6-mo 40.58%
1-year 107.00%
3-year 119.89%
5-year 645.07%
YTD 2.86%
2021 163.07%
2020 -59.74%
2019 175.96%
2018 155.26%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7414 seconds.